Iluvatar CoreX H1 Revenue Surges, But Core Ops Still Loss-Making: what are the key facts?

H1 2026 revenue reached RMB 946 million, a 191.6% year-over-year increase.

Iluvatar CoreX H1 Revenue Surges, But Core Ops Still Loss-Making: what are the key facts?

Adjusted net profit was RMB 246 million, primarily driven by RMB 760 million in unrealized equity gains.

Iluvatar CoreX H1 Revenue Surges, But Core Ops Still Loss-Making: what are the key facts?

Excluding investment income, the company posted an actual operating loss of approximately RMB 654 million.

Iluvatar CoreX H1 Revenue Surges, But Core Ops Still Loss-Making: what are the key facts?

Inference chip revenue share rose to 69.2%, while gross margin declined to 17.2%.

Physix Frontier · News Briefing Card (enbrief · Aug 30, 2026)

Iluvatar CoreX H1 Revenue Surges, But Core Ops Still Loss-Making

KEY FACTS

H1 2026 revenue reached RMB 946 million, a 191.6% year-over-year increase.
Adjusted net profit was RMB 246 million, primarily driven by RMB 760 million in unrealized equity gains.
Excluding investment income, the company posted an actual operating loss of approximately RMB 654 million.
Inference chip revenue share rose to 69.2%, while gross margin declined to 17.2%.

KEY DATA

RMB 946MH1 Revenue

RMB 760MEquity Investment Income

17.2%Adjusted Gross Margin

52,000 unitsCumulative Chips Delivered

PHYSIX OBSERVATION

Iluvatar CoreX's 'profitability' is a financial illusion; the core contradiction lies in low-margin inference chips failing to cover high R&D and inventory costs. This reflects the domestic GPU industry's shift from hype to brutal commercial validation: mid-tier players lacking pricing power and technical moats cannot escape reliance on non-recurring items, even with AI Agent tailwinds. Self-sustaining cash flow remains the existential threshold.

Source: enbrief original report ↗